Biofrontera Ag · XETR:B8FK
Biofrontera — Investor Presentation (November 2020)
16 slides from Biofrontera's investor presentation, November 2020
Slide 1: Analyst Presentation
ANALYST PRESENTATION Prof. Dr. Hermann Lübbert, CEO November 2020
Slide 2: Forward-Looking Statements and Risks
DISCLAIMER FORWARD-LOOKING STATEMENTS AND RISKS This presentation contains forward-looking statements including, without limitation, statements containing the words “expects”, “future”,“potential” and words of similar import. Such forward looking statements are based on the currently held beliefs an
Slide 3: Biofrontera At-a-Glance
COMPANY SUMMARY BIOFRONTERA AT-A-GLANCE HEADQUARTERS PRODUCTS SALES FORCE FINANCIAL STOCK MARKET PERFORMANCE Headquartered in Biofrontera’s Dedicated sales teams in Revenue growth from Listed on the Frankfurt Leverkusen, Germany Photodynamic Therapy the U.S., Germany, Spain EUR 4.1 million in 2015 t
Slide 4: Biofrontera Group Financial Results
FINANCIAL OVERVIEW BIOFRONTERA GROUP FINANCIAL RESULTS In EUR million (IFRS) 2014 2015 2016 2017 2018 2019 9M 2019 9M 2020 Total revenue 3.1 4.1 6.1 12.0 21.1 31.3 19.1 20.8 Product sales 3.1 4.1 5.0 10.6 21.0 30.6 18.7 14.3 thereof US revenues 0 0 1.2 6.3 14.9 23.3 13.6 9.1 Operating income (9.6) (
Slide 5: Revenue Development 2012-2020
REVENUE REVENUE DEVELOPMENT 2012-2020 In EUR million +48% 31.3 • Lower 9M 2020 product Germany Europe +98% sales due to pandemic US compensated by one-time 21.1 Development projects 20.9 payment from licensing +114% 19.1 Downpayments agreement 12.0 • 2020 forecast for sales revenue between EUR 34 to
Slide 6: Growth Milestones 2016 - 2020
TRACK RECORD GROWTH MILESTONES 2016 - 2020 Approved indication extensions for Ameluz® FDA approval of Ameluz® for the lesion- and field-directed treatment of AK on the face and scalp (May 2016) Treatment of basal cell carcinomas (BCC) in Europe (January 2017) Daylight-PDT for actinic keratosis
Slide 7: Where Do We Want to Be in 5 Years?
GOALS WHERE DO WE WANT TO BE IN 5 YEARS? Revenue: between EUR 200 million and EUR 400 million in 2025 Ameluz® has become the PDT and XepiTM the topical antibiotic “standard of care” Market penetration gains achieved for PDT in the actinic keratosis and non- melanoma skin cancer market Acne indicatio
Slide 8: How Do We Want to Achieve Our Goals?
CORPORATE STRATEGY HOW DO WE WANT TO ACHIEVE OUR GOALS? Biofrontera‘s strategy is to optimize the market potential and market positioning of its current product portfolio. Growth Core Markets R&D Licensing Opportunity With our two prescription We focus on our core Our research efforts for We seek li
Slide 9: AK: Before and After Ameluz PDT
ACTINIC KERATOSIS TREATMENT WITH PDT AK: BEFORE AND AFTER AMELUZ® PDT US dermatologists have traditionally preferred cryotherapy based on speed of treatment and good remuneration. Benefits of Ameluz® PDT vs. cryotherapy: • Higher efficacy with better clearance and recurrence rates • Serves medical n
Slide 10: Ameluz Market Potential for Actinic Keratosis
AK MARKET IN THE US AMELUZ® MARKET POTENTIAL FOR ACTINIC KERATOSIS The US is Biofrontera‘s largest market This 3% segment represents a $ 140M drug market 3% 13% cryotherapy Total AK population (US) topicals ~52,950,0001 PDT Treated AK patients ~12,961,0002 84% PDT Treated Patients 24%2 of AK patient
Slide 11: Optimizing the Market Potential of Ameluz in the USA
PRODUCT STRATEGY OPTIMIZING THE MARKET POTENTIAL OF AMELUZ® IN THE USA 2021 2021 2022/23 2022/23 2025/26 TBD Product development Label expansion Label expansion Label expansion Label expansion Label expansion Approval of larger Approval for the Approval for the Indication: Indication: Indication: PD
Slide 12: Actinic Keratosis Market in the EU
AK MARKET IN THE EU ACTINIC KERATOSIS MARKET IN THE EU AK market by treatment option EU market 2.1 million** prescriptions for AK per year 7% size 7% One relevant competitor in the PDT market (Metvix®/Luxerm®) PDT • Two superiority claims in the Ameluz® EU label 86% competition • Ameluz® is the lead
Slide 13: Impetigo: Before and After Xepi Treatment
TREATMENT OF IMPETIGO WITH XEPI IMPETIGO: BEFORE AND AFTER XEPI™ TREATMENT XEPI™ advantages* • Approved for impetigo due to Staphylococcus aureus or Streptococcus pyogenes, including antibiotic resistant strains such as MRSA • Approved for adults and pediatric patients 2 months of age and older • Re
Slide 14: Market Potential of Xepi in Dermatology Alone
TOPICAL ANTIBIOTICS MARKET IN THE US MARKET POTENTIAL OF XEPITM IN DERMATOLOGY ALONE Generic Mupirocin: Utilization by specialty Dermatology XepiTM dermatology patients Pediatrics 10% 14% Mupirocin treated Nurse 100%1 dermatology patients Practitioner ~1,148,140 21% All Others 31% 63%2 Xepi™ eligibl
Slide 15: Optimizing Xepi Market Access
PRODUCT STRATEGY OPTIMIZING XEPITM MARKET ACCESS Reimbursement Payors Copay card Distribution Unrestricted access. Program redesigned – Independent Community effective April 1, 2020: Pharmacies (ICP) are MARKET Patient compliance Over 150 M lives covered • rebalances cost-sharing being added where A
Slide 16: Contact Details
CONTACT US CONTACT DETAILS Prof. Hermann Luebbert, PhD h.luebbert@biofrontera.com CEO & Founder Thomas Schaffer t.schaffer@biofrontera.com CFO Pamela Keck p.keck@biofrontera.com Head of Investor Relations Biofrontera AG Phone +49 (214) 876 32 -0 Hemmelrather Weg 201 Fax +49 (214) 876 32 -90 D-51377